Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.

Wang B, Qian H, Yiu SM, Sun J, Zhu G.

Eur J Med Chem. 2014 Jan;71:366-73. doi: 10.1016/j.ejmech.2013.10.062. Epub 2013 Nov 1.

PMID:
24361480
2.

Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.

Wang Z, Qian H, Yiu SM, Sun J, Zhu G.

J Inorg Biochem. 2014 Feb;131:47-55. doi: 10.1016/j.jinorgbio.2013.10.017. Epub 2013 Oct 31.

PMID:
24239912
3.

Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1.

Zhu G, Chang P, Lippard SJ.

Biochemistry. 2010 Jul 27;49(29):6177-83. doi: 10.1021/bi100775t.

4.

Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.

Yao H, Ji M, Zhu Z, Zhou J, Cao R, Chen X, Xu B.

Bioorg Med Chem. 2015 Feb 15;23(4):681-93. doi: 10.1016/j.bmc.2014.12.071. Epub 2015 Jan 8.

PMID:
25614115
5.

Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA.

Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ.

Bioorg Med Chem. 2008 Dec 1;16(23):10121-8. doi: 10.1016/j.bmc.2008.09.074. Epub 2008 Oct 14.

6.

Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells.

Nguewa PA, Fuertes MA, Cepeda V, Alonso C, Quevedo C, Soto M, Pérez JM.

Med Chem. 2006 Jan;2(1):47-53.

PMID:
16787355
7.

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.

Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL.

Breast Cancer Res Treat. 2012 Jul;134(2):649-59. doi: 10.1007/s10549-012-2106-5. Epub 2012 Jun 8.

8.

In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells.

Le TV, Suh JH, Kim N, Park HJ.

Bioorg Med Chem Lett. 2013 May 1;23(9):2642-6. doi: 10.1016/j.bmcl.2013.02.094. Epub 2013 Mar 1. Erratum in: Bioorg Med Chem Lett. 2013 Jun 15;23(12):3673.

PMID:
23522835
9.

Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.

Zhu Q, Wang X, Hu Y, He X, Gong G, Xu Y.

Bioorg Med Chem. 2015 Oct 15;23(20):6551-9. doi: 10.1016/j.bmc.2015.09.026. Epub 2015 Sep 16.

PMID:
26422786
10.

Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.

Li H, Hu Y, Wang X, He G, Xu Y, Zhu Q.

Bioorg Med Chem. 2016 Oct 1;24(19):4731-4740. doi: 10.1016/j.bmc.2016.08.016. Epub 2016 Aug 11.

PMID:
27561983
11.

Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.

Zhu G, Myint M, Ang WH, Song L, Lippard SJ.

Cancer Res. 2012 Feb 1;72(3):790-800. doi: 10.1158/0008-5472.CAN-11-3151. Epub 2011 Dec 16.

12.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

PMID:
14709739
13.

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146. Epub 2014 Mar 20.

14.

New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules.

Lee YR, Yu DS, Liang YC, Huang KF, Chou SJ, Chen TC, Lee CC, Chen CL, Chiou SH, Huang HS.

PLoS One. 2013;8(2):e56284. doi: 10.1371/journal.pone.0056284. Epub 2013 Feb 25.

15.

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.

Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53. Review.

PMID:
20645701
16.

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B.

Mol Cancer Ther. 2003 Apr;2(4):371-82.

17.

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, Pérez JM.

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):39-53. Review.

PMID:
18221025
18.

Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.

Giannini G, Battistuzzi G, Vesci L, Milazzo FM, De Paolis F, Barbarino M, Guglielmi MB, Carollo V, Gallo G, Artali R, Dallavalle S.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):462-6. doi: 10.1016/j.bmcl.2013.12.048. Epub 2013 Dec 18.

PMID:
24388690
19.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ.

Clin Cancer Res. 2003 Jul;9(7):2711-8.

20.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z.

J Med Chem. 2002 Nov 7;45(23):4961-74.

PMID:
12408707

Supplemental Content

Support Center